Full Text View
Tabular View
Study Results
Related Studies
Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
This study has been completed.
Study NCT00441116   Information provided by GlaxoSmithKline
First Received: February 27, 2007   Last Updated: June 23, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Androgenetic Alopecia
Additional conditions recognized in this trial
Alopecia
More general conditions related to this trial
Hair Diseases
Hypotrichosis
Pathological Conditions, Anatomical
Skin Diseases
Interventions listed in this trial
Dutasteride 0.5mg oral tablets
Additional drug interventions recognized in this trial
Dutasteride
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services